- INC Research Holdings, Inc. stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
INC Research Holdings, Inc. stock price
INC Research Holdings, Inc. latest news:
'Huge business rate rise' for small firms
Inflation-busting increases are looming for thousands of shops in England, says research firm CVS.
BRIEF-TSMC orders machinery equipment worth T$2.1 bln
* Says it orders machinery equipment worth T$2.1 billion
($69.43 million) from Lam Research International Sarl, Applied
Materials South East Asia Pte Ltd
LG, Qualcomm join hands for autonomous driving
LG Electronics says it has joined hands with Qualcomm to jointly research and develop autonomous driving technologies
BRIEF-Ignyta announces proposed public offering of common stock
Ignyta Inc(RXDX). * Ignyta(RXDX) announces proposed public offering of common stock. * Ignyta Inc (RXDX) says commenced an underwritten public offering of $125.0 million of shares of its common stock. * Ignyta Inc (RXDX) says anticipates using net proceeds from offering to fund research and development activities for its development programs Source text for Eikon: Further company coverage:
Why Analysts Are Stepping All Over Themselves Chasing Lam Research Higher
Lam Research revenue, profit beat estimates as chip demand booms
Lam Research Corp(LRCX), a maker and supplier of chip equipment, reported better-than-expected quarterly profit and revenue as the company benefited from chipmakers stepping up investments in technology and capacity. The company's shares, which touched a record high of $195.49 on Tuesday, have soared 84 percent this year.
Lam Research shares slip after earnings beat
Lam Research Corp. shares slipped in the extended session Tuesday even after the chip-making equipment company's quarterly results topped Wall Street estimates. Lam shares declined 0.4% to $193.87 after hours, following a 1.1% rise in the regular session. Shares are up 84% for the year. The company reported fiscal first-quarter net income of $590.7 million, or $3.21 a share, compared to $263.8 million, or $1.47 a share, in the year-ago period. Adjusted earnings were $3.46 a share. Revenue rose to $2.48 billion from $1.63 billion in the year-ago period. Analysts surveyed by FactSet had estimated earnings of $3.27 a share on revenue of $2.46 billion.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Lam Research reports results for quarter ended September 24, 2017
* Lam Research Corporation reports financial results for the
quarter ended September 24, 2017
BRIEF-Amgen and Boston Children's Hospital enter into neuroscience research collaboration
Amgen Inc(AMGN). * Amgen(AMGN) - co, Boston Children's Hospital entered into neuroscience research collaboration aimed at identifying novel pain targets. * Amgen Inc (AMGN) - one-year collaboration will focus on patients with genetic anomalies of pain sensitivity Source text for Eikon: Further company coverage:
BRIEF-Cerveau Technologies announces research collaboration agreement with Janssen Pharmaceuticals
* Says announced a research collaboration agreement with
Janssen Pharmaceuticals Inc for use of MK-6240
Apple may not be able to ramp iPhone X production until December, analyst says
Apple Inc. may not ramp up production volume on its flagship iPhone X until December, according to a Friday research note from Cascend Securities. Apple shares are up less than 1% to $156.89 in late-session trading. Though iPhone X sales are set to kick off with pre-orders on Oct. 27 and availability Nov. 3, the manufacturing and supply chain partners Apple uses are privately saying that volumes will not be ready in November. Cascend analyst Eric Ross told MarketWatch that normally device manufacturers build up inventory and ensure it's in the hands of retail outlets and carriers so gadgets are available to consumers on launch day. "But they don't seem to be doing it this year," he said. As for the iPhone 8, consumer interest is "OK but not tremendous" and customers are not buying as much as Cascend expected, the note says. While iPhone 8 supply is good, the discounts have not yet been enough give wireless carriers incentives to attract more customers to two-year contracts. Apple stock is up 35% this year, with the S&P 500 index up 13.9%. The Dow Jones Industrial Average , of which Apple is a component, is up 15.8% this year.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment
Shares of Aerie Pharmaceuticals Inc. were halted for trading Friday, as the U.S. Food and Drugs Administration reviews a new drug application for a treatment for glaucoma and ocular hypertension. The FDA's dermatologic and opthalmic drugs advisory committee will meet at 8.30 a.m. Eastern to review Rhopressa, an eye drop which, if approved, would be the only once-daily product targeting the trabecular meshwork, which is the eye's main fluid drain and the tissue responsible for the pressure on the eyes felt in glaucoma. Glaucoma is a disease in which damage to the optic nerve leads to vision loss. It's the second leading cause of blindness, according to the Glaucoma Research Foundation. Aerie shares have gained 66% in 2017, while the S&P 500 has gained 14%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Santander Aims to Bolster FCA Relationship With Executive Shuffle
Santander Consumer USA announced a series of executive changes last week, leaving many asking why? One explanation may be that it’s a way to bolster its relationship with Fiat Chrysler Automobiles, Christopher Donat, managing director of equity research at Sandler O’Neill, told Auto Finance News. “[FCA] is their singleRead More
Snap stock surges 11.4% in best trading day since IPO
Snap Inc. enjoyed its best day of trading Wednesday since its March 2 debut in the public market, rising 11.4% to $15.98. The company has struggled since the stock soared to a record $27.09 in the days following the initial public offering, and has plunged 22.8% in the past six months. The S&P 500 index has risen 8.4% in the past six months. In a research note sent to clients Wednesday, Credit Suisse raised its price target to $20 from $17, citing an increase in its North American daily active user estimates.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
EU pesticide debate needs more "independent expertise" - Macron
PARIS, Oct 11 (Reuters) - France and the European Union need
independent scientific experts to guide them on divisive
environmental issues such as pesticides, French President
Emmanuel Macron said, criticising some research as prone to
BRIEF-Alibaba Group says to invest over $15 bln in R&D over next 3 years
* Alibaba group holding - announced launch of global
research program, alibaba damo academy, designed to increase
technological collaboration worldwide
Richard Thaler wins Nobel for work in behavioral economics
The Nobel economics prize has been awarded to Richard Thaler of the University of Chicago for research showing how people's economic choices _ whether on savings or game shows like "Deal or No Deal" _ are not always rational
Flexion shares surge 18% on news of FDA approval for non-opioid knee pain injection
Flexion Therapeutics Inc. shares surged 18% in afternoon trade Friday on news that the company's non-opioid injection for osteoarthritis knee pain has been approved by the Food and Drug Administration. The injection, Zilretta, provides pain relief for 12 weeks. The company expects it will be available in the U.S. by the end of the month, with a full commercial launch in mid-November, at a price of $570 a dose (the figure refers to the injection's wholesale acquisition cost, which is the price a drugmaker offers middleman wholesalers). Osteoarthritis, the most common form of arthritis, is a painful joint disease. Zilretta uses microscopic spherical particles to deliver a combination of a common, short-acting corticosteroid with a poly lactic-co-glycolic acid, the company said. Though there is an urgent need for new non-opioid pain medications, startlingly little progress has been made, MarketWatch reported this summer. Zilretta "may avoid the disruptive blood glucose spikes that can be seen with corticosteroid use in patients coping with both knee OA and type 2 diabetes," said Dr. Steven Russell, assistant professor of medicine at Massachusetts General Hospital Diabetes Research Center. Flexion shares have surged 40% over the last three months, compared with a nearly 6% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Immunogen shares fall after secondary share offering announced
Immunogen Inc. shares fell in the extended session Wednesday after the biotech company announced a secondary offering of shares. Immunogen shares fell 10% to $7.05 after hours. The company said it plans to offer 13 million shares, and provide underwriters with up to 2 million shares to cover overallotments. Jefferies, Leerink Partners and RBC Capital Markets are listed as underwriters. Immunogen intends to use proceeds to finance research and development, clinical trials and for other corporate purposes. Immunogen has 115.5 million shares outstanding.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Caterpillar's stock rallies to record after an upbeat comment from the most bearish analyst
Shares of Caterpillar Inc. climbed 1% toward a record in midday trade Wednesday, after some upbeat comments about used equipment pricing from the analyst who is the most bearish on the mining and farm equipment maker. The stock was the biggest percentage gainer within the Dow Jones Industrial Average , with the $1.19 price gain accounting for about 8 points of the Dow's 35-point gain. Analyst Sameer Rathod at Macquarie Research said an analysis of used-equipment listings suggests the pace of price declines in September from a year ago has slowed from the previous month, and that inventory continues to decline, which indicates the U.S. earth-moving markets are recovering. This upbeat outlook comes despite Rathod having an underperform rating on the stock, and a price target of $86, which is 32% below current levels, and the lowest of the 24 analysts surveyed by FactSet. His bearishness stems from the believe that expectations are running ahead of fundamentals, as "all of the macro factors that allowed [Caterpillar] to have strong results have peaked." Caterpillar's stock has soared 18.4% over the past three months, while the Dow has gained 5.6%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Silicon Valley's race gap is getting worse, not better, new research shows
Diversity efforts by Bay Area tech companies have boosted white women's careers. Everyone else? Not so much. Minorities are falling further behind.
Hey, Procter & Gamble: You're lagging, and you can blame (or listen to) Millennials
Research shows that Millennials rebel hard against old brands. To survive, old brands need to listen.
Merck discontinues development program for a Hep-C treatment
Merck & Co. said Friday it would discontinue the development of the investigational combination regimens MK-3682B and MK-3682C for the treatment of chronic hepatitis C, after a review of available Phase 2 efficacy data. The drug maker also considered the growing number of treatment options available, including Merck's own Zepatier. "We will continue to study ZEPATIER to understand even more about its role in treating chronic hepatitis C infection and will continue to work with others to help bring Zepatier to appropriate patients with chronic hepatitis C genotype 1 or 4 infection, the genotypes which make up the majority of patients with chronic hepatitis C infection," said Eliav Barr, senior vice president at Merck Research Laboratories. The stock, which was inactive in premarket trade, has slipped 0.1% over the past three months, while the SPDR S&P Pharmaceuticals ETF has shed 2.3% and the Dow Jones Industrial Average has gained 5.1%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Lam Research says CEO's FY 2017 total compensation was $11.2 mln
* Lam Research Corp says CEO Martin Anstice's FY 2017
total compensation was $11.2 million versus $10.6 million in FY
2016 - SEC filing
Source text: (http://bit.ly/2wmnogh)
Further company coverage:
McDonald's stock surge after an upgrade accounts for more than half of the Dow's gain
Shares of McDonald's Corp. climbed $3.65, or 2.4%, in afternoon trade Thursday, to pace the Dow Jones Industrial Average's gainers, after an analyst upgrade. The price gain was adding about 25 points to the Dow's price, which was up 37 points. Longbow Research analyst Alton Stump raised his rating on the fast-food giant to the equivalent of buy, according to FactSet. Stump's price target of $183 is 16% above current levels, and 6.2% above the average target of $172.31 of the 32 analysts surveyed by FactSet. The stock, which is 2.4% below the Sept. 11 record close of $161.53, has soared 30% year to date, while the Dow has gained 13%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Gold settles modestly higher after touching lowest levels since mid-August
Gold prices end higher Thursday, edging up after notching a six-week low as the U.S. dollar retreated from its highest level in a month. "Futures and options traders may be running scared of the [Federal Reserve's] sudden claim of getting sober and preparing to raise rates, but private investors in physical gold don't believe it," said Adrian Ash, head of research at BullionVault. "They're using this price drop to rebuild positions after taking profits over the summer," he said. December gold rose 90 cents, or less than 0.1%, to settle at $1,288.70 an ounce. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
McDonald's shares jump as an analyst predicts a burger sales surge
Longbow Research raises its rating for McDonald's to buy from neutral, saying the restaurant chain will report sales above Wall Street expectations.
The Zacks Analyst Blog Highlights: Apple, Snap, Intel and Corning
For Immediate Release Chicago IL September 27 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
Ligand Pharma, Chipotle Mexican Grill, Arcelormittal, Ichor Holdings and Micron Technology highlighted as Zacks Bull and Bear of the Day
For Immediate Release Chicago IL September 27 2017 Zacks Equity Research Ligand Pharma Nasdaq 160 LGND 160 Free Report as the Bull of the Day Chipotle Mexican Grill NYSE 160 CMG 160 Free Report as the Bear of the Day In addition Zacks Equity Research
Health care sector falls as likelihood of ACA repeal rises; UnitedHealth's stock leads Dow losers
The health care sector traded broadly lower Tuesday, amid concerns over the potential effects of the Graham-Cassidy bill, which some analysts say is becoming increasingly likely to repeal and replace the Affordable Care Act. The SPDR Health Care Select Sector ETF shed 0.9% in afternoon trade, with 56 of its 62 components trading lower. Among the XLV's most heavily-weighted components, UnitedHealth Group's stock dropped 1.8% to pace the Dow Jones Industrial Average's decliners. The price decline of $3.61 was shaving 25 points off the Dow, which was up 44 points. Analyst Ana Gupte at Leerink Research said the bill could lead to "greater earnings downside in the near term than previous House and Senate bills for ACA-levered stocks." Among companies that Gupte said are at particular risk, shares of Centene Corp. slumped 4.6% and Molina Healthcare Inc. gave up 6.1%. Elsewhere, shares of Aetna Inc. fell 3.4%, Humana Inc. slid 3.2%, Cigna Corp. declined 1.9% and Anthem Inc. was down 2.0%. Gupte said diversified managed care organizations (MCOs) like Humana and Cigna are more defensive, though exposure should be manageable for UnitedHealth, Aetna and Anthem. The XLV has gained 4.3% over the past three months, while the S&P 500 has tacked on 2.2%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Independent Bank Corp.INDB
Independent Bank CorporationIBCP
Independent Bank Group, IncIBTX
Industrial Services of America, Inc.IDSA
Infinity Pharmaceuticals, Inc.INFI
Infinity Property and Casualty CorporationIPCC
Information Services Group, Inc.III